Los Angeles Capital Management
LXEO icon

Los Angeles Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Los Angeles Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$213K Buy
37,071
+25,516
+221% +$181K ﹤0.01% 1126
2025
Q4 		$109K Buy
11,555
+480
+4% +$4.38K ﹤0.01% 1396
2025
Q3 		$73.5K Buy
+11,075
New +$53.6K ﹤0.01% 1327

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Los Angeles Capital Management's LXEO Position: Q1 2026 in Review

Los Angeles Capital Management increased its Lexeo Therapeutics (LXEO) stake by 221% in Q1 2026, buying an estimated $181K and bringing the position to 37,071 shares worth $213K. The position accounts for ﹤0.01% of the portfolio, ranked #1126.

Los Angeles Capital Management first reported a position in LXEO in Q3 2025 and has held it in 3 quarters since. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Los Angeles Capital Management held 37,071 shares of Lexeo Therapeutics worth $213K as of Q1 2026.
  • Los Angeles Capital Management bought 25,516 Lexeo Therapeutics shares in Q1 2026, an estimated $181K.
  • Lexeo Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1126 holding.
  • Los Angeles Capital Management first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.